Ulrika Wählby Hamrén, PhD

AstraZeneca, Gothenburg, Sweden
Mölndal, Vastra Gotaland, Sweden

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 1934 - Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

  Friday, October 13, 2023
  1:45 PM – 1:57 PM US ET